Skip to Main Content
Table 2.
Comparison of clinical characteristics between CMR and non-CMR CML patients
Clinical parametersCMR (n = 51) median (range)Non-CMR (n = 42) median (range)P values
Age (yr) 60.7 (28–85) 59.5 (23–79) 0.9446 
Sex,a female 20 (39.2) 15 (35.7) 0.7287 
Weight (kg) 60.3 (42–84) 60.7 (45–102) 0.3965 
Sokal risk (low/int./high) 35/13/2 24/11/2 0.8688 
EUTOS risk (low/high) 42/3 31/2 0.9140 
CML duration (mo) 84.8 (22.4–229.4) 77.3 (13.2–186.3) 0.6576 
Prior IFN-αa 8 (15.7) 11 (26.2) 0.2112 
Duration of IM treatment (mo) 84.3 (22.4–116.6) 77.1 (12.6–122.4) 0.5036 
Actual daily IM dose (mg/d) 400 (161.7–400) 400 (66.7–400) 0.9098 
Median time to CCyR (mo)    
From diagnosis to CCyR 6.6 (2.5–60.1) 6.5 (1–103.3) 0.8728 
From IM therapy to CCyR 5.7 (2–46.5) 4.8 (0.5–76.7) 0.5431 
Median time to MMR (mo)    
From diagnosis to MMR 15.8 (4.4–185.6) 30.5 (4.4–167.8) 0.0937 
From IM therapy to MMR 15.1 (3.2–76.1) 19.6 (3.6–93.9) 0.2429 
IM trough concentration (ng/ml) 981.8 (336.3–2,687.7) 1151.7 (124.4–2,624.1) 0.5597 
BIM deletiona 4 (7.8) 7 (16.6) 0.1898 
Clinical parametersCMR (n = 51) median (range)Non-CMR (n = 42) median (range)P values
Age (yr) 60.7 (28–85) 59.5 (23–79) 0.9446 
Sex,a female 20 (39.2) 15 (35.7) 0.7287 
Weight (kg) 60.3 (42–84) 60.7 (45–102) 0.3965 
Sokal risk (low/int./high) 35/13/2 24/11/2 0.8688 
EUTOS risk (low/high) 42/3 31/2 0.9140 
CML duration (mo) 84.8 (22.4–229.4) 77.3 (13.2–186.3) 0.6576 
Prior IFN-αa 8 (15.7) 11 (26.2) 0.2112 
Duration of IM treatment (mo) 84.3 (22.4–116.6) 77.1 (12.6–122.4) 0.5036 
Actual daily IM dose (mg/d) 400 (161.7–400) 400 (66.7–400) 0.9098 
Median time to CCyR (mo)    
From diagnosis to CCyR 6.6 (2.5–60.1) 6.5 (1–103.3) 0.8728 
From IM therapy to CCyR 5.7 (2–46.5) 4.8 (0.5–76.7) 0.5431 
Median time to MMR (mo)    
From diagnosis to MMR 15.8 (4.4–185.6) 30.5 (4.4–167.8) 0.0937 
From IM therapy to MMR 15.1 (3.2–76.1) 19.6 (3.6–93.9) 0.2429 
IM trough concentration (ng/ml) 981.8 (336.3–2,687.7) 1151.7 (124.4–2,624.1) 0.5597 
BIM deletiona 4 (7.8) 7 (16.6) 0.1898 

BIM, BCL2L11 gene; CCyR, complete cytogenetic response; EUTOS, European Treatment and Outcome Study; IM, imatinib; int., intermediate; MMR, major molecular response.

a

Data presented as number (%) of patients.

Close Modal

or Create an Account

Close Modal
Close Modal